Back to search results

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Abroad (travel likely)RecruitingPHASE2

Conditions

Thymoma · Thymic Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Stanford Cancer Institute, Palo Alto, California, United States

    Contact: Study coordinator (Monica Loza) · lozam@stanford.edu · 650-724-1430
    Contact: Principal Investigator (Heather A Wakelee, MD)

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Matt Hayhurst) · mh2340@georgetown.edu · 202-784-3877
    Contact: Principal Investigator (Chul Kim, MD)

  • University of Chicago Medical Center, Chicago, Illinois, United States

    Contact: Study coordinator (Paige Pribble) · ppribble@bsd.uchicago.edu · 773-702-8133
    Contact: Principal Investigator (Marina Garassino, MD)

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

    Contact: Study coordinator (Oncology Clinical Research Referral Office) · OncologyResearchReferral@hmhn.org · 551-996-1777
    Contact: Principal Investigator (Martin Gutierrez, MD)
Study leads

  • Chul Kim, MD

    Principal Investigator

    Chul.Kim@gunet.georgetown.edu

View source on ClinicalTrials.gov(opens in a new tab)